Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07730281
PHASE2
PRA-216 COPD Safety and Biomarker Study
Sponsor: Prana Therapies Inc
View on ClinicalTrials.gov
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).
Official title: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-08-01
Completion Date
2027-09-01
Last Updated
2026-07-28
Healthy Volunteers
No
Interventions
DRUG
PRA-216
biologic
DRUG
Placebo
matching placebo for PRA-216